<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01260974</url>
  </required_header>
  <id_info>
    <org_study_id>1768P</org_study_id>
    <secondary_id>2008-007950-36</secondary_id>
    <nct_id>NCT01260974</nct_id>
  </id_info>
  <brief_title>Caspofungin as Prophylaxis in High Risk Liver Transplantation Recipients</brief_title>
  <acronym>CPHRLTX</acronym>
  <official_title>Pilot Study: Efficacy of Caspofungin for Antifungal Prophylaxis for Selected High Risk Liver Transplant Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera di Padova</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Azienda Ospedaliera di Padova</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to determine viable use of caspofungin in post-OLTx patients, and to
      demonstrate in particular the effectiveness, understood as the ability to reduce the
      incidence of invasive fungal infections, and to assess the ability to reduce the risk and
      incidence of side effects (toxicity) which may arise in transplant patients treated with
      other drugs, especially in individuals recognized as high risk (e.g. renal failure).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prophylactic use of anti-fungal drugs is crucial in order to decrease the incidence of
      invasive fungal infections in transplantation patients.

      Invasive fungal infections (IFI) ---organ-related or systemic infections--- are in fact one
      of the most important causes of morbidity and mortality in patients undergoing solid organ
      transplantation (respectively, 70% and 100%).

      The rationale of the proposed study is to evaluate a new protocol for the prevention of IFIs
      through the use of a newly introduced anti-fungal, caspofungin (commercial name: Cancidas),
      to be used for primary prophylaxis of fungal infections post-OLTx and to compare to drugs
      already in use (eg. amphotericin B, fluconazole), until 21 days after liver transplantation.

      The aim of this study is determine viable use of caspofungin in post-OLTx patients, and to
      demonstrate in particular the effectiveness, understood as the ability to reduce the
      incidence of invasive fungal infections, and to assess the ability to reduce the risk and
      incidence of side effects (toxicity) which may arise in transplant patients treated with
      other drugs, especially in individuals recognized as high risk (e.g. renal failure).

      The possibility of reducing the risk of fungal infections in liver transplant patients
      (usually between 7 and 42%) is therefore an important clinical goal.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">November 2012</completion_date>
  <primary_completion_date type="Anticipated">November 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Invasive Fungal Infection Free follow-up</measure>
    <time_frame>1 month</time_frame>
    <description>Invasive Fungal Infection free control 1 month after beginning treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerance to treatment.</measure>
    <time_frame>3 months</time_frame>
    <description>Tolerance to treatment, with major focus on nephrotoxicity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study group mortality</measure>
    <time_frame>3 months</time_frame>
    <description>Assessment of study group mortality, compared to control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study group morbidity</measure>
    <time_frame>3 months</time_frame>
    <description>Assessment of study group morbidity, compared to control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Invasive Fungal Infection-free percentage of study group</measure>
    <time_frame>1 month</time_frame>
    <description>Invasive Fungal Infection-free percentage of study group, evaluated at 1 month from beginning of study and assessment of mortality and morbidity in the control group</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Fungemia</condition>
  <condition>Mycoses</condition>
  <arm_group>
    <arm_group_label>Caspofungin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caspofungin</intervention_name>
    <description>50mg/dd for 21dd, starting within 24h from Liver Transplantation.</description>
    <arm_group_label>Caspofungin</arm_group_label>
    <other_name>Cancidas</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients shortlisted for liver transplantation

          -  negative pregnancy test for fertile female patients 7 days prior enrollment

          -  patients who can adequately communicate with study responsibles, who can understand
             and answer to protocol requirements

        At least one of the following criteria:

          -  MELD score â‰¥25

          -  liver transplantation for acute liver failure

          -  liver re-transplantation

          -  fever without bacterial or viral infection

          -  biliodigestive

          -  re-laparatomy after LTx

          -  post LTx pancreatitis

          -  post LTx dialysis or renal insufficiency

        Exclusion Criteria:

          -  Patients enrolled in other clinical trial or those having received other experimental
             drugs 4 weeks prior to enrollment

          -  Patients with a known fungal infection (based on the EORTC/MSG criteria)

          -  Patients with history of hypersensitivity to the drug, or other counterindications

          -  Patients with a diagnosed Severe Hepatic insufficiency (CTP &gt;9)

          -  Physical or hematochemical alterations

          -  Clinically relevant psychological alterations in the 2 weeks preceding enrollment such
             as to interfere, in the researchers opinion, with the goal of the study

          -  Patients being treated with Ciclosporin A

        Subjects being removed from the trial shall be replaced.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Umberto Cillo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliera Universitaria di Padova</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniele Neri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliera Universitaria di Padova</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Umberto Cillo, MD</last_name>
    <phone>+390498218624</phone>
    <email>cillo@unipd.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura Saracino, MBS</last_name>
    <phone>+390498218624</phone>
    <email>lasaracino@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Umberto Cillo, MD</last_name>
      <phone>+390498218624</phone>
      <email>cillo@unipd.it</email>
    </contact>
    <contact_backup>
      <last_name>Laura Saracino, MBS</last_name>
      <phone>+390498218624</phone>
      <email>lasaracino@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Umberto Cillo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniele Neri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giacomo Zanus, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrizia Boccagni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Enrico Gringeri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francesco D'Amico, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alessandro Vitale, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paolo Feltracco, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dino Sgarabotto, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pasquale Bonsignore, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marina Polacco, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Enrico Lodo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Davide Du Puis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura Saracino, MBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.fegatochirurgia.com/</url>
    <description>Hepatobiliary surgery and Liver Transplantation Unit, University Hospital of Padua (Italy)</description>
  </link>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2010</study_first_submitted>
  <study_first_submitted_qc>December 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2010</study_first_posted>
  <last_update_submitted>July 17, 2012</last_update_submitted>
  <last_update_submitted_qc>July 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera di Padova</investigator_affiliation>
    <investigator_full_name>Prof. Umberto Cillo</investigator_full_name>
    <investigator_title>Director of the Hepatobiliary Surgery and Liver Transplantation Unit</investigator_title>
  </responsible_party>
  <keyword>Invasive fungal infections</keyword>
  <keyword>Liver Transplantation</keyword>
  <keyword>Organ Transplantation</keyword>
  <keyword>Mycoses</keyword>
  <keyword>Fungus Diseases</keyword>
  <keyword>Antifungal Agents</keyword>
  <keyword>Invasive Mycosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Fungemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caspofungin</mesh_term>
    <mesh_term>Echinocandins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

